A policeman receives a dose of COVISHIELD, a Covid-19 vaccine manufactured by Serum Institute of India, at a vaccination centre in Ahmedabad. - Reuters
NEW DELHI, Feb 5 (Reuters): Pfizer Inc said on Friday it had withdrawn an application for emergency-use authorisation of its Covid-19 vaccine in India, after failing to meet the drug regulator's demand for a local safety and immunogenicity study.
The decision means the vaccine will not be available for sale in the world's two most populous countries, India and China, in the near future. Both countries are running their immunisation campaigns using other products.
Already a subscriber? Log in.
Win a prize this Mother's Day by subscribing to our annual plan now! T&C applies.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
